2020/03
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study. Eur Neurol. 2020 Mar 18:1-9. doi: 10.1159/000505778. Epub ahead of print. PMID: 32187609.F.I.4.387.
Autores/as:
Meca-Lallana J, Ayuso T, Martínez-Yelamos S, Durán C, Contreras Martín Y, Herrera Navarro N, Pérez Sempere A, Álvarez-Cermeño JC, Millán Pascual J, Meca-Lallana V, Romero Sevilla R, Ricart J.
Servicio:
Neurología Complejo Hospitalario Universiatrio de Badajoz
Tipo:
Artículo
Materia: